Functional Dyspepsia: When Your Upper Gut Hurts and the Tests Come Back Normal

The burning, the bloating, the uncomfortable fullness that descends with every meal — these are the hallmarks of dyspepsia, a word derived from the Greek for "bad digestion." For millions of Australians, these upper gut symptoms are a daily reality. Most assume they have reflux, reach for an antacid, and never look deeper. But for a significant proportion of people — perhaps as many as one in ten adults — the symptoms are not explained by reflux, ulcers, or any visible abnormality on gastroscopy. Instead, they have functional dyspepsia: a condition that is real, physiologically grounded, and, with the right approach, highly treatable.

What Is Functional Dyspepsia?

Functional dyspepsia (FD) is defined as persistent or recurrent symptoms arising from the upper gastrointestinal tract — the stomach and first part of the small intestine — in the absence of any structural abnormality to explain them. Under the Rome IV diagnostic criteria, it encompasses two primary symptom patterns: postprandial distress syndrome (PDS), characterised by meal-induced fullness, early satiety, and upper bloating; and epigastric pain syndrome (EPS), characterised by burning or pain in the upper abdomen that may or may not be related to meals. Many patients experience a blend of both.

What makes functional dyspepsia challenging — both for patients and clinicians — is precisely the absence of obvious structural disease. Gastroscopy, the definitive test, comes back normal. Blood tests and imaging are unremarkable. And yet the symptoms persist, disrupting meals, work, sleep, and quality of life. Patients are often left feeling dismissed or, worse, told it is "all in their head." It is not.

The Mechanisms Behind the Misery

Research over the past two decades has dramatically shifted our understanding of functional dyspepsia. We now know it is a disorder of gut-brain interaction — a condition involving dysregulation of the complex communication network between the enteric nervous system (your gut's own neural circuitry), the central nervous system, and the gut microbiome. Several distinct mechanisms drive symptoms, and understanding which is dominant in any given patient is key to choosing effective treatment.

Impaired gastric accommodation is one key driver. Normally, the stomach relaxes and expands to accommodate a meal — a reflex mediated by the vagus nerve. In many FD patients, this accommodation reflex is blunted. The stomach fails to expand adequately, leading to a rapid rise in intragastric pressure and the sensation of uncomfortable fullness after only a small amount of food. Patients describe feeling full after just a few bites of a meal that should be easily manageable.

Gastric hypersensitivity is another mechanism. The visceral nerves supplying the stomach become sensitised, firing pain signals in response to stimuli — a moderately full stomach, for instance — that would not trouble a person without FD. This visceral sensitisation explains why patients can experience severe discomfort from meals that appear entirely unremarkable in volume, and why standard doses of acid-suppressing medication often provide only partial relief.

Delayed gastric emptying — known as gastroparesis when severe — occurs in a subset of FD patients. Food lingers in the stomach longer than it should, contributing to bloating, nausea, early satiety, and in some cases vomiting. This can be formally assessed with a gastric emptying study, in which a radiolabelled meal is consumed and its transit through the stomach is tracked over several hours.

And then, for a meaningful subset of patients, there is Helicobacter pylori.

The H. pylori Connection

One of the most clinically important — and often overlooked — aspects of functional dyspepsia management is the relationship with Helicobacter pylori infection. Guidelines from major gastroenterological bodies, including the Gastroenterological Society of Australia, recommend testing for and eradicating H. pylori in all patients with uninvestigated or confirmed functional dyspepsia. The rationale is compelling: approximately 10–15 percent of patients who successfully eradicate H. pylori will experience long-term resolution of their dyspepsia — a modest but clinically meaningful and durable benefit that no other drug therapy consistently matches.

In functional dyspepsia, H. pylori eradication is the only intervention shown to provide durable long-term symptom relief in a subgroup of patients. It is not just about ulcer prevention — it matters for functional symptoms, too.

The challenge arises when standard eradication therapy fails. First-line triple therapy — a proton pump inhibitor with two antibiotics — now has eradication rates of only 70–80 percent in parts of Australia due to rising antibiotic resistance, particularly to clarithromycin. For patients who have failed one or more courses of treatment, access to salvage regimens becomes essential. Dr. Tu offers advanced eradication protocols at Mater Private Hospital combining vonoprazan — a potassium-competitive acid blocker (P-CAB) that provides superior and more consistent acid suppression than standard PPIs, completely independent of CYP2C19 genetic polymorphisms — with rifabutin, amoxicillin, and bismuth. This regimen achieves eradication rates of approximately 92 percent even in antibiotic-resistant cases, representing a genuine advance for patients who have been stuck in a cycle of treatment failure.

What About Proton Pump Inhibitors?

Proton pump inhibitors remain first-line pharmacotherapy in functional dyspepsia, and with good reason. They are effective in a meaningful proportion of patients — particularly those with epigastric pain syndrome and predominant acid-related symptoms such as burning. A 4–8 week trial of a standard-dose PPI is recommended before escalating to other treatments, and for many patients, especially those with coexisting gastro-oesophageal reflux, they provide satisfactory and well-tolerated relief.

However, it is worth understanding what PPIs do not do. They do not address impaired gastric accommodation, visceral hypersensitivity, or delayed gastric emptying — the dominant mechanisms in many FD patients. Long-term PPI use also has well-documented downstream effects on the gut microbiome: by reducing gastric acid, PPIs alter the pH environment of the upper gastrointestinal tract, potentially facilitating bacterial colonisation of areas that should remain relatively sterile, and modifying the composition of the small intestinal microbiome. For patients who have been taking PPIs for months or years without a formal reassessment of whether they remain appropriate, a specialist review is worthwhile.

Vonoprazan represents an interesting development in acid suppression more broadly. Unlike conventional PPIs, whose effectiveness is diminished in patients with common variants of the CYP2C19 metabolising enzyme — variants carried by up to 20 percent of East Asian populations — vonoprazan's mechanism of action is completely independent of CYP2C19. This makes it more reliably and consistently effective across diverse patient populations, with a faster onset of action and sustained acid suppression even during the first few doses. Its evolving role in functional dyspepsia management is an active area of clinical research.

Beyond Acid: Treating the Whole Condition

For patients with confirmed functional dyspepsia — particularly those with postprandial distress syndrome and features of impaired gastric accommodation — acid suppression alone is rarely sufficient. A comprehensive management approach incorporates several additional elements, tailored to the patient's predominant mechanism.

Dietary modification is a practical and often helpful starting point. Smaller, more frequent meals reduce the pressure placed on a stomach with impaired accommodation. High-fat meals slow gastric emptying further, as does lying down after eating — both habits worth modifying. Spicy foods and carbonated beverages commonly exacerbate symptoms and are worth trialling as exclusions. That said, overly restrictive diets that eliminate broad food groups are rarely necessary and risk becoming counterproductive, particularly when they reduce social participation around meals.

Low-dose neuromodulators — principally tricyclic antidepressants such as amitriptyline at 10–25 mg nightly, or mirtazapine — have the best evidence base for treating visceral hypersensitivity and improving gastric accommodation in functional dyspepsia. These are prescribed at doses well below those used in the management of depression, and their mechanism of action in FD is peripheral: they modulate gut-brain signalling pathways rather than acting primarily on mood centres. It is important for patients to understand this distinction, as concerns about being prescribed an antidepressant for a gut condition are common and can impede adherence.

Prokinetic agents — medications that accelerate gastric emptying — have a role when delayed emptying is the dominant mechanism. Several options are available in Australia, including metoclopramide and domperidone, though their use requires careful consideration of dose, duration, and side effect profile. Their benefit is most pronounced in patients with objective evidence of delayed gastric emptying rather than in the broader FD population.

Increasingly, the gut microbiome is entering the conversation around functional dyspepsia. Emerging evidence suggests that dysbiosis — an imbalance in the composition and diversity of the gut microbial community — may contribute to FD symptoms via effects on visceral sensitivity, mucosal immune function, and the gut-brain axis. Microbiome sequencing can provide clinically useful insights for patients with complex or treatment-refractory presentations, helping to guide whether targeted microbiome interventions are appropriate.

When to Seek Specialist Review

Functional dyspepsia, while carrying no risk of malignancy in itself, shares its symptom profile with conditions that can be serious: gastric cancer, coeliac disease, peptic ulcer disease, and gastroparesis can all present with overlapping upper gut symptoms. Gastroscopy remains the definitive investigation for anyone with alarm features — unexplained weight loss, difficulty swallowing, vomiting blood or material resembling coffee grounds, new-onset symptoms after the age of 55, iron deficiency anaemia, or a first-degree family history of gastric cancer. These features should prompt urgent specialist review and should not be managed conservatively.

For patients without alarm features who have been self-managing upper gut symptoms with over-the-counter antacids or long-term PPIs without formal evaluation, a structured specialist consultation can make a meaningful difference. A thorough clinical assessment, targeted investigation, H. pylori testing and eradication where indicated, and a considered treatment plan — one that addresses the actual mechanism driving symptoms rather than simply suppressing acid indefinitely — is the appropriate path forward.

If you have been living with persistent upper abdominal discomfort, early satiety, post-meal bloating, or nausea that has not responded adequately to standard treatments, it is time to seek specialist review. Dr. Jeffrey Tu consults at Mater Private Hospital and brings expertise across the full spectrum of upper gastrointestinal conditions, including functional dyspepsia, H. pylori eradication — including complex refractory cases — and acid-related disorders. A GP referral is all that is required to book a consultation. Your symptoms deserve a proper explanation, and an effective treatment plan is within reach.